Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 first-in-human study of SAR445877 in advanced solid tumors
MOH_2023-08-22_012892Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Aug 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of SAR445877 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC) and 3 more (3 arms), sponsored by Sanofi. Primary endpoints: Safety, Pharmacokinetics and 2 more. Started Aug 2023; status: recruiting.
02
Drugs
SAR445877
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on MOH_2023-08-22_012892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-22_012892.